EE288 A Cost-Effectiveness Analysis of Biologic Compared with Chemical Disease Modifying Drugs in Treating Multiple Sclerosis in US

Multiple sclerosis (MS) is a chronic immune mediated neurodegenerative disease of the central nervous system with US prevalence of ∼900,000 and high economic burden. Medical care for MS involves high-cost diseases modifying therapies (DMT). The current study aims to compare the cost-effectiveness of best-selling biologics (Ocrelizumab, Natalizumab, Alemtuzumab) with best-selling chemical drugs (Dimethyl Fumarate, Fingolimod) as DMT for MS to support better clinical decision-making.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research